The article discusses research being done on cardioprotection with angiotensin-converting enzyme (ACE) inhibitors in patients with cancer. It references the study "Cardiac toxicity: Using ACE to prevent anthracycline-induced left ventricular dysfunction and cardiomopathy," by C.A. Kobza, which was published in the June 2021 issue of the "Clinical Journal of Oncology Nursing."